TransMedics Group, Inc. $TMDX Stake Trimmed by Montanaro Asset Management Ltd

Montanaro Asset Management Ltd lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 21.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 101,939 shares of the company’s stock after selling 28,647 shares during the quarter. TransMedics Group accounts for about 3.5% of Montanaro Asset Management Ltd’s holdings, making the stock its 11th biggest position. Montanaro Asset Management Ltd’s holdings in TransMedics Group were worth $12,401,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Kensington Investment Counsel LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $1,926,000. Fieldview Capital Management LLC purchased a new position in TransMedics Group during the 3rd quarter worth approximately $1,716,000. Citigroup Inc. grew its position in TransMedics Group by 29.3% during the 3rd quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after purchasing an additional 17,414 shares in the last quarter. Fred Alger Management LLC grew its position in TransMedics Group by 303.8% during the 3rd quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock worth $16,913,000 after purchasing an additional 113,408 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in TransMedics Group by 78.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 47,048 shares of the company’s stock valued at $5,279,000 after purchasing an additional 20,750 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. TD Cowen reduced their target price on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Needham & Company LLC dropped their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $134.50.

TransMedics Group Price Performance

TMDX stock opened at $78.79 on Friday. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 17.91 and a beta of 1.91. The company has a 50 day moving average of $83.39 and a two-hundred day moving average of $112.79.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The company’s revenue was up 21.2% on a year-over-year basis. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.